|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00459940 |
|
Date of registration:
|
12/04/2007 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
|
Scientific title:
|
"Can Growth Hormone's Lipolytic and Insulin-Antagonistic Effects be Modified by Peroxisome Proliferator-Activated Gamma Agonists?" |
|
Date of first enrolment:
|
September 2004 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00459940 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Denmark
| | | | | | | |
|
Contacts
|
|
Name:
|
Jens OL Jorgensen, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Aarhus |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Growth hormone replaced (minimum 6 months) growth hormone deficient men
- Age over 18 years
Exclusion Criteria:
- Ischemic coronary disease, defined by EF<0.6, former myocardial infarction, angina
pectoris or actual treatment of cardiac insufficiency
- Actual or former malignancy, except intracranial neoplasia that caused the
participants pituitary disease, provided that there was clinical evidence for
permanent remission
- Blood donation within 6 months
- Excessive alcohol consumption
- Known allergic reaction from contents of test drug
- Radioactive radiation exposure in terms of treatment or study enrollment within one
year
- Liver insufficiency
- Insulin treatment
Age minimum:
19 Years
Age maximum:
71 Years
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Growth Hormone Deficiency
|
|
Intervention(s)
|
|
Drug: Pioglitazone
|
|
Primary Outcome(s)
|
|
Lipid oxidation
|
|
Circulating FFA level
|
|
FFA turnover
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|